William Blair analyst Brandon Vazquez has maintained their bullish stance on PEN stock, giving a Buy rating on October 27.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Brandon Vazquez has given his Buy rating due to a combination of factors including the positive data from the STORM-PE trial, which aligns with one of the more optimistic scenarios for Penumbra. The trial results have been well-received, and the focus now shifts to educating medical professionals about the advantages of mechanical thrombectomy for patients at intermediate-high risk. Despite a recent decline in share prices, which Vazquez attributes to market misunderstanding rather than company fundamentals, he sees this as a buying opportunity.
Vazquez anticipates that the successful outcomes from the trial could lead to updates in clinical guidelines, although this process may take some time. He remains confident that the current valuation, which is 5.5 times the estimated sales for 2026, is attractive given the potential for accelerated business growth. The analyst’s outlook is further supported by the expectation that the STORM-PE results will drive increased adoption and market penetration in the coming year.
According to TipRanks, Vazquez is an analyst with an average return of -0.8% and a 42.47% success rate. Vazquez covers the Healthcare sector, focusing on stocks such as Ceribell, Inc., Align Tech, and Dexcom.